Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Epitomee MedicalEPTMF 21 Cash-to-Debt is 1.46 as of Jun. 2026, which is 76% below its 10-year median of 5.99. GuruFocus rates EPTMF with a GF Score™ of 21/100. The stock has 3 warning signs investors should review. Among 840 Medical Devices & Instruments companies, Epitomee Medical ranks worse than 52.02% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Epitomee Medical's cash to debt ratio for the quarter that ended in Jun. 2026 was 1.46.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Epitomee Medicalcould pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for Epitomee Medical's Cash-to-Debt or its related term are showing as below:
EPTMF'
s Cash-to-Debt Range Over the Past 10 Years
Min: 1.46 Med: 5.99 Max: 120.87
Current: 1.46
During the past 8 years, Epitomee Medical's highest Cash to Debt Ratio was 120.87. The lowest was 1.46. And the median was 5.99.
EPTMF's Cash-to-Debt is ranked worse than 52.02% of 840
companies
in the Medical Devices & Instruments industry
Industry Median: 1.635
vs EPTMF: 1.46
Epitomee Medical (OTCPK:EPTMF) Cash-to-Debt Explanation
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Epitomee Medical Cash-to-Debt Related Terms
Epitomee Medical Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Epitomee Medical's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Medical Devices subindustry, Epitomee Medical's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Epitomee Medical Cash-to-Debt vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Epitomee Medical's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Epitomee Medical's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Epitomee Medical (EPTMF) has a Cash-to-Debt of 1.46 as of Jun. 2026. This is 76% below median its historical median of 5.99. Over the past decade, Epitomee Medical's Cash-to-Debt has ranged from 1.46 to 120.87. According to the industry distribution chart, Epitomee Medical ranks #437 out of 840 companies in the Medical Devices & Instruments industry, placing it in the top 52%.
Is Epitomee Medical's Cash-to-Debt too high?
Epitomee Medical's current Cash-to-Debt of 1.46 is 76% below median its 10-year median of 5.99. Over the past 10 years, this metric has ranged from a low of 1.46 to a high of 120.87. The Medical Devices & Instruments industry median Cash-to-Debt is 1.64. Epitomee Medical's value of 1.46 is 10.7% below this industry median. Based on the distribution chart, Epitomee Medical ranks #437 out of 840 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Epitomee Medical has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Epitomee Medical's Cash-to-Debt compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Epitomee Medical ranks #437 out of 840 companies for Cash-to-Debt. This places Epitomee Medical in the lower half of its industry. The industry median Cash-to-Debt is 1.64. Epitomee Medical's value of 1.46 is 10.7% below this benchmark. Historically, Epitomee Medical's own Cash-to-Debt has ranged from 1.46 to 120.87 over the past decade. While the company's 10-year median is 5.99 vs. the industry median of 1.64, Epitomee Medical has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Medical Devices & Instruments company?
The median Cash-to-Debt among Medical Devices & Instruments companies is 1.64, based on 840 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Epitomee Medical's current Cash-to-Debt of 1.46 is 10.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median Cash-to-Debt is 1.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Epitomee Medical's current Cash-to-Debt is 1.46, which is 76% below median its own 10-year median of 5.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Epitomee Medical stock overvalued right now?
Epitomee Medical (EPTMF) has a current Cash-to-Debt of 1.46. The current Cash-to-Debt is 1.46, which is 76% below median its 10-year median of 5.99 and 10.7% below the Medical Devices & Instruments industry median of 1.64. Epitomee Medical's overall GF Score™ is 21/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Epitomee Medical (EPTMF), the current Cash-to-Debt is 1.46 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EPTMF has been successfully added to your 
